and B (acetonitrile with 0.1% TFA), A/B = 95%/5% at 0-1 min, A/B = 95%/5% to A/B = 5%/95% at 1-11 min, A/B = 5%/95% at 11-13 min, A/B = 95%/5% 13-16 min. HPLC standard curves Compounds were accurately weighed and dissolved in acetonitrile-water (1:1) or methanol-water (1:1), based on their solubility, to make a stock solution of 5.0 mM. The stock solution was diluted with water to 2.0 mM, 1.0 mM, 0.50 mM, 0.20 mM and 0.10 mM. All the solutions with known concentrations were analysed in the HPLC following the analytical HPLC method. HPLC peak area S (mAU 2 ) and compound concentration C (mM) were recorded and fitted to a straight line using EXCEL software, giving the standard curve as the format of S = aC + b.
Chiral HPLC method
Method
Representative HPLC Traces
Supplementary Figure 6 Chiral HPLC chromatogram of chemoenzymatic cascades to trolline and analogues. 
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General Procedures and Compound Characterization
Protein Expression Glycerol stocks of E. coli BL21 (DE3) cells transformed with plasmids (His-tag NCS or variants, with 29 amino acids deleted at the C-terminus) were incubated in terrific broth (TB, Fluka Analytical company) medium (20 mL) containing 50 µg/mL of kanamycin for 16 h at 37 o C, 250
rpm. The starter culture (4 mL) was then incubated with TB medium (100 mL) containing 50 µg/mL of kanamycin for 1 h at 37 o C, 250 rpm until OD 600 = 1.0 detected by the spectrophotometer (JENWAY 7315). Isopropyl β-D-1-thiogalactopyranoside (IPTG, final concentration was 500 µM) was added and the mixture was incubated for 5 h at 25 o C, 250 rpm. The expression cultures were centrifuged at 12000 rpm for 10 min at 4 o C and the supernatant was removed. Cell pellets were collected and stored at -20 o C. 3 Protein Purification Cell Pellets were resuspended in 10% v/v original culture volume of Bugbuster (Novagen Bugbuster ® 10X Protein Extraction Reagent, diluted to 1X prior to usage). The mixture was centrifuged for 30 min at 4 o C, 12000 rpm. The supernatant was then filtered using a 0.22 µm cellulose acetate syringe filter (Millex ® -GP) and passed through the Ni-NTA column (a PD-10 column filled with 2.3 mL of Nickel-NTA resin Agarose, Invitrogen) previously equilibrated with binding buffer A (100 mM HEPES, 100 mM NaCl, 20 mM imidazole, pH 7.5). The column was washed with binding buffer B (100 mM HEPES, 100 mM NaCl, 40 mM imidazole, pH 7.5) and eluted with elution buffer (100 mM HEPES, 100 mM NaCl, 500 mM imidazole, pH 7.5) until no protein was left on the column (checked by Bio-Rad Bradford 1x Dye Reagent). The eluent containing pure protein was exchanged into HEPES buffer (100 mM HEPES, pH 7.5) using a PD-10 desalting column (GE Healthcare Sephadex TM G-25 M).
Protein purity was tested by SDS-PAGE (Gel results referred to supplementary Figure 4 ) and protein concentration was tested with a Thermo Scientific NANODROP 2000c Spectrophotometer at 280 nm. Glycerol (final concentraion 10% v/v) was added to the pure protein solution and stored at -80 o C.
3
Protein Purity Test Protein sample was analysed by SDS-12% polyacrylamide gel electrophoresis (SDS-PAGE) on Mini-Protein Precast Gels (Bio-Rad company). Briefly, the protein composition was prepared by mixing 10 µL loading buffer, 10 µL DTT and 20 µL testing sample. The prepared mixture as well as a Ladder protein marker (10-25 kDa, New England Biolabs) were boiled at 95 o C for 15 min and spun at 13000 rpm for 10 min. The supernatants were loaded to the gels and run (200 V for 40 min). The gel was then washed with distilled water and treated with instant blue overnight. A ProteinSimple camera and AlphaImager MiNi software were used to take a picture of the gel.
Chemical Reagent Flash silica chromatography was carried out using Geduran ® Si 60 (40-63 µm). Thin layer chromatography (TLC) used aluminium backed silica gel plates from Merck Keiselgel and were visualised using ultra-violet light (254 nm). The solvents and chemicals were purchased from Sigma Aldrich, Alfa Aesar, Santa Cruz Biotechnology and were used as supplied unless indicated otherwise.
Chemical Characterization Melting points were tested using Stuart (SMP11) and DigiMelt MPA161 melting point machines. and methyl 6-oxohexanoate 10. For amines 13, 14 and 15 reacted with 5, the first reactions (step a) were performed for 18 h and the second reactions (cyclisations) were for 2 h (13 and 15) and 4 h (14). HPLC yields were calculated based on standard curves established with pure compounds (see Table 1 in the main text).
For enzyme reactions, HEPES buffer (100 mM HEPES, pH 7.5) was added with a final concentration of DMSO (1% v/v), dopamine 1 (10 mM), methyl 4-oxobutanoate 5 (15 mM), sodium ascorbate (10 mM) and △29TfNCS (wild type, 0.1 mg/mL) in a 1.5 mL capped microcentrifuge tube. The reactions were flushed with argon, sealed and shaken for 3 h at 37 o C, 500 rpm. Reactions were monitored by taking 100 µL sample diluting with water/HCl (10 µL HCl + 440 µL water) and analysed by HPLC following the analytical HPLC method. Then 800 µL of the reaction mixtures were treated with 80 µL HCl (1 M) and 120 µL sodium carbonate solution (1 M) and shaken for 2 h at 60 o C, 500 rpm. Similar procedures were used with methyl 5-oxopentanoate 7 and methyl 6-oxohexanoate 10. For amines 13, 14 and 15 reacted with 5, the first reactions (step a, 0.5 mg/mL WT-△29TfNCS) were 6 h (13 and 15) or 18 h (14) and the second reactions (cyclisations) were for 2 h (13 and 15) and 4 h (14). HPLC yields were calculated based on standard curves as above (see Table 1 in the main text). Figure  3) . Time-dependent study of NCS reactions Dopamine hydrochloride (7.6 mg, 0.04 mmol, 10 mM), sodium ascorbate (8.0 mg, 0.04 mmol, 10 mM), DMSO (40 µL, 1% v/v) and WT-△29TfNCS (final concentration 0.1 mg/mL) were added to HEPES buffer (pH 7.5, 100 mM) to make a final volume of 4 mL. The mixture was seperated into 4 fractions (equal volume 1 mL) into capped microcentrifuge tubes.
Screening of reaction conditions for second-step (cyclization
To each fraction was added freshly purified methyl 4-oxobutanoate 5 (95%, 1.8 µL, 0.06 mmol) except one control reaction. Similar procedures were applied with methyl 5-oxopentanoate 7 and methyl 6-oxohexanoate 10. All mixtures were shaken under argon for up to 3 h at 37 o C, 500 rpm. At each time point 15 min, 30 min, 60 min, 120 min and 180 min, 100 µL of the reaction mixture was collected, quenched by aq. HCl (10 µL, 1 M) and diluted with H 2 O (440 µL). Collected samples were analysed by HPLC following the analytical HPLC method. The depletion percentage of dopamine at each time point was calculated following the formula: (S control -S experiment )/ S control ×100%, S was the HPLC peak area of dopamine. Average depletion of dopamine of three independent reactions and standard errors were calculated and displayed in Supplementary Figure 2 . Note that dopamine depletion was used to monitor the reactions to reduce complexity of the assay due to linear and cyclic products being formed.
Computational docking Computational docking calculations were conducted using AutoDock Vina 4 , implemented through UCSF Chimera and the Opal web service. Ligand structures were prepared and energy minimised on the molview.org server prior to docking. PDB structure 5NON was prepared by converting selenomethionines to methionines, removing ligands and adding hydrogens as previously. 5 The docking prameters were: center_x = -16.99; center_y = -5.81; center_z = 15.42; size_x = 16.56; size_y = 14.22; size_z = 22.15; energy_range = 3; exhaustiveness = 8; num_modes = 10. Ten binding modes were predicted for each ligand, and only top ranked modes which showed interactions in line with the dopamine-first mechanism 2,5 were analysed. To a solution of δ-valerolactone (10.0 g, 99.9 mmol) in methanol (30 mL), concentrated sulfuric acid (0.4 mL) was added and the mixture was stirred for 2 h at 65 o C. It was then cooled to 0 o C and H 2 O (30 mL) was added. The solution was adjusted to pH 8.0 by adding aq. Na 2 CO 3 (1 M). The mixture was extracted with ether (60 mL, then 2 × 30 mL), washed with brine (2 × 30 mL), dried (Na 2 SO 4 ) and concentrated under vacuum to give the alcohol as a colourless oil (5.14 g, 39%), which was used directly in the next step. 1 To a solution of ε-caprolactone (10.0 g, 87.6 mmol) and methanol (30 mL), concentrated sulfuric acid (0.4 mL) was added, and the mixture was heated at reflux for 2 h. It was then cooled to room temperature, and water (30 mL) was added. 
Trolline (2)
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Synthesis of (±)-trolline 2. (i) Small-scale (1 mL) KPi reaction.
The procedure described on pS11 was used and reaction yields determined by HPLC. Trolline 2 was formed in 97% yield in a para:ortho isomeric ratio of 18:1 (see Supplementary Figure 8B ).
(ii) Preparative scale reaction for product isolation and characterisation. To a solution of dopamine hydrochloride (76 mg, 0.40 mmol), ascorbic acid (70 mg, 0.40 mmol), KPi buffer (20 mL, pH 6, 0.3 M) and CH 3 CN (20 mL) was added methyl 4-oxobutanoate 5 (64 µL, 0.60 mmol). The mixture was heated at 60 o C and stirred for 18 h under argon. The pH of the solution was then adjusted to 7.5 by adding aq. Na 2 CO 3 (1 M) and stirred for another 4 h at 60 o C under argon. The product was extracted with ethyl acetate (3 × 30 mL), the organic layer dried (Na 2 SO 4 ) and evaporated to give a yellow solid. The residue was re-suspended in aq. HCl (10 mL, 1 M) and dimethyl carbonate (DMC) (10 mL), and the aqueous layer was washed with DMC (3 × 5 mL). The DMC fractions were combined and washed with aq. HCl (3 × 5 mL, 1 M). The aqueous phase was co-evaporated with methanol at 55 o C to obtain a white solid, (±)-trolline 2 (71 mg, 81%) in a para:ortho isomeric ratio of 34:1. The characterization data is given below for the (S)-isomer.
Synthesis of (-)-trolline (S)-2. (i) Small-scale (1 mL) NCS reaction.
The procedure described on pS11 was used and reaction yield determined by HPLC. Trolline (S)-2 was was formed in 75% yield (see Supplementary Figure 8D ) and no minor isomeric product was observed. The ee was 95% by chiral HPLC (of intermediate (S)-6: see Supplementary Figure 6A and Table S2 ).
(ii) Preparative scale reaction for product isolation and characterisation. Dopamine hydrochloride (76 mg, 0.40 mmol) and sodium ascorbate (80 mg, 0.40 mmol) were added to HEPES buffer (38.9 mL, pH 7.5, 100 mM). Methyl 4-oxobutanoate 5 (64 µL, 0.60 mmol) in DMSO (0.4 mL) was added, followed by WT-△29TfNCS (final concentration 0.1 mg/mL). The mixture was stirred at 37 o C under argon. After 6 h, the reaction was quenched with aq. HCl (4 mL) and adjusted to pH 7.5 by adding aq. Na 2 CO 3 (1 M). The mixture was then stirred for another 4 h at 60 o C under argon and extracted with ethyl acetate (4 × 20 mL). The organic layer was washed with brine (3 × 40 mL), dried (Na 2 SO 4 ) and evaporated to give the crude product. The residue was re-suspended in aq. HCl (10 mL, 1 M) and DMC (10 mL), and the aqueous layer was washed with DMC (3 × 5 mL). DMC fractions were combined and washed with aq. HCl (3 × 5 mL, 1 M). The aqueous phase was co-evaporated with methanol at 55 o C to obtain a white precipitate, (-)-trolline (S)-2 (65 mg, 74% 
9,10-Dihydroxy-1,2,3,6,7,11b-hexahydro-4H-pyrido[2,1-a]isoquinolin-4-one (9)
Synthesis of 9. (i) Small-scale (1 mL) KPi reaction.
The procedure described on pS11 was used and reaction yield determined by HPLC. Compound 9 was formed in 89% yield in a para:ortho isomeric ratio of 9:1 (see Supplementary Figure 9B ).
(ii) Reaction for product isolation and characterisation.
To a solution of dopamine hydrochloride (19 mg, 0.10 mmol), ascorbic acid (18 mg, 0.10 mmol), KPi buffer (5 mL, pH 6, 0.3 M) and CH 3 CN (5 mL) was added methyl 5-oxopantanoate 7 (22 µL, 0.15 mmol; 93% purity). The mixture was stirred at 60 o C for 18 h under argon. The pH of the solution was then adjusted to 7.5 by adding aq. Na 2 CO 3 (1 M) and stirred for another 4 h at 60 o C under argon. The reaction mixture was purified directly by preparative HPLC following semi-preparative HPLC method C to obtain a white solid 9 (16 mg, 69%) in a para:ortho isomeric ratio of 50:1 by NMR. The characterization data is given below for the (S)-isomer. 
Synthesis of (S)-9. (i) Small-scale (1 mL) NCS reaction.
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The procedure described on pS11 was used and reaction yield determined by HPLC. Compound (S)-9 was was formed in 96% yield (see Supplementary Figure 9D ) and no minor isomeric product was observed. The ee was determined to be 96% by chiral HPLC (of intermediate (S)-8:see Supplementary Figure 6B and Table S2 ).
(ii) Preparative scale reaction for product isolation and characterisation. Dopamine hydrochloride (76 mg, 0.40 mmol) and sodium ascorbate (80 mg, 0.40 mmol) were added to HEPES buffer (38.9 mL, pH 7.5, 100 mM). Methyl 5-oxopantanoate 5 (80 µL, 0.60 mmol) in DMSO (0.4 mL) was then added to the solution, followed by WT-△29TfNCS (final concentration 0.1 mg/mL). The mixture was stirred at 37 o C under argon. After 6 h, the reaction was quenched with aq. HCl (4 mL, 1 M) and adjusted to pH 7.5 by adding aq. Na 2 CO 3 (1 M). The mixture was then stirred for another 4 h at 60 o C under argon and extracted with ethyl acetate (4 × 20 mL). The organic layer was washed with brine (3 × 40 mL), dried (Na 2 SO 4 ) and evaporated to give the crude product. The residue was resuspended in aq. HCl (10 mL, 1 M) and DMC (10 mL), and the aqueous layer was washed with DMC (3 × 5 mL). The DMC fractions were combined and washed with aq. HCl (3 × 5 mL, 1 M). The aqueous phase was co-evaporated with methanol at 55 o C to obtain a white precipitate (S)-9 (81 mg, 87% 
Methyl (1S)-4-(6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl)butanoate.TFA (8)
Synthesis of (S)-8. Dopamine hydrochloride (19 mg, 0.10 mmol) and sodium ascorbate (20 mg, 0.10 mmol) were added to HEPES buffer (9.3 mL, pH 7.5, 100 mM). Methyl 5-oxopantanoate 5 (21 µL, 0.15 mmol) in DMSO (0.10 mL) was then added to the solution, followed by WT-△29TfNCS (final concentration 0.10 mg/mL). The mixture was stirred at 37 o C under argon for 6 h. The reaction mixture was centrifuged to remove protein, and the supernatant was washed with ethyl acetate (3 × 5 mL 
Methyl 5-(6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl)pentanoate (11)
Synthesis of 11. (i) Small-scale (1 mL) KPi reaction.
The procedure described on pS11 was used and reaction yield determined by HPLC. Compound 11 was formed in 72% yield in a para:ortho isomeric ratio of 7:1 (see Supplementary Figure 10A ).
(ii) Reaction for product isolation and characterisation.
To a solution of dopamine hydrochloride (9.5 mg, 0.05 mmol), ascorbic acid (9.0 mg, 0.051 mmol), KPi buffer (2.5 mL, pH 6, 0.3 M) and CH 3 CN (2.5 mL) was added methyl 6-oxohexanoate 7 (11 µL, 0.075 mmol). The reaction was stirred at 60 o C for 18 h under argon, then purified using a C 18 reverse phase semi-preparative column (semi-preparative HPLC method A) to obtain a white solid, 11 as the TFA salt (5.0 mg, 26%) in a para:ortho isomeric ratio of 7: 
Synthesis of (S)-11. (i) Small-scale (1 mL) NCS reaction.
The procedure described on pS11 was used and reaction yield determined by HPLC. Compound (S)-11 was was formed in 92% yield (see Supplementary Figure 10B ) and no minor isomeric product was observed. The ee was determined to be >99.5% by chiral HPLC (see Supplementary Figure 6C and Table S2 ).
(ii) Reaction for product isolation and characterisation. Dopamine hydrochloride (10.0 mg, 0.053 mmol) and sodium ascorbate (11.0 mg, 0.056 mmol) were added to HEPES buffer (4.86 mL, pH 7.5, 100 mM). Methyl 6-oxopantanoate 7 (11 µL, 0.075 mmol) in DMSO (50 µL) was added to the solution, followed by WT-△29TfNCS (final concentration 0.1 mg/mL) to make the total volume 5 mL. The mixture was stirred at 37 o C under argon. The reaction was quenched after 3 h by adding HCl (0.5 mL, 1 M) and centrifuged for 10 min at 4000 rpm to remove the protein. The supernatant was purified by preparative HPLC following semi-preparative HPLC method A. The purified product was further washed with diethyl ether (3 × 2 mL) and dried under high vacuum to obtain a white solid (S)-11 as the TFA salt (13 mg, 63%). No minor isomeric product was observed. The characterisation data was identical to that above for the racemate and 
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vacuum. The residue was dissolved in methanol (20 mL) and evaporated to obtain the crude product, which was purified by SiO 2 column chromatography (CH 2 Cl 2 and MeOH (with 5% Et 3 N), 25:1 to 5:1), giving 3-methoxyphenethylamine as a pale yellow oil (440 mg, 68% 3-Methoxyphenethylamine (350 mg, 2.31 mmol) was added to anhydrous dichloromethane (10 mL) and the reaction was stirred at -78 o C. Then boron tribromide (5.1 mL, 5.1 mmol; 1 M) was added dropwise.
The mixture was warmed to room temperature and stirred for 12 h. Methanol (10 mL) was added dropwise and the reaction was stirred for another 3 h, then concentrated under vacuum. The residue was dissolved in methanol (10 mL) and evaporated under vacuum, which was repeated several times. The product 13 was obtained as the HBr salt (502 mg, 99%). 
2-(4-Fluoro-3-hydroxyphenyl)ethylamine hydrobromide (15)
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To a stirred solution of sodium carbonate (2.0 g, 19 mmol) and methylamine hydrochloride (2.0 g, 30 mmol) in ethanol (25 mL) was added 4-fluoro-3-methoxybenzaldehyde (9.4 g, 61 mmol) in EtOH (20 mL). Nitromethane (5.3 mL, 94 mmol) was added and the mixture was sealed and left in dark at room temperature. Three days later, the yellow precipitate formed was filtered and washed with cold ethanol, giving the 2-(4-fluoro-3-methoxyphenyl)nitroethylene as yellow crystals (6.3 g, 52% yield Hydroxy-1,5,6,10b-tetrahydropyrrolo [2,1-a] isoquinolin-3(2H)-one (16) Racemic synthesis of 16.
8-
(i) Small-scale (1 mL) KPi reaction. The procedure described on pS11 was used and reaction yield determined by HPLC. Compound 16 was formed in 97% yield in a para:ortho isomeric ratio of 6:1 (see Supplementary Figure 11A ).
(ii) Reaction for product isolation and characterisation. 
Synthesis of (S)-16. (i) Small-scale (1 mL) NCS reaction.
The procedure described on pS11 was used and reaction yield determined by HPLC. Compound (S)-16 was was formed in 51% yield (see Supplementary Figure 11C ) and no minor isomeric product was observed. The ee was determined to be 93% by chiral HPLC (see Supplementary Figure 6D and Table  S2 ).
(ii) Reaction for product isolation and characterisation. 2-(3-Hydroxyphenyl)ethylamine 13 (HBr salt) (11.0 mg, 0.050 mmol) and sodium ascorbate (9.0 mg, 0.045 mmol) were added to HEPES buffer (4.02 mL, pH 7.5, 100 mM). Methyl 4-oxobutanoate (9 µL, 0.075 mmol, 95% purity) in DMSO (0.5 mL, 10% v/v) was added to the solution, followed by WT- buffer (and 1% DMSO) under Ar with sodium ascorbate, Na 2 CO 3 (1 M) and at pH 7-8, the ee afterwards was the same within experimental error to that before being subjected to these reaction conditions (0 to 1% ee difference). The procedure described on pS11 was used and reaction yield determined by HPLC. Compound 18 was formed in 100% yield in a para:ortho isomeric ratio of 13:1 (see Supplementary Figure 12A ).
Supplementary
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To a solution of 2-(4-fluoro-3-hydroxyphenyl)ethylamine (HBr salt) 15 (47 mg, 0.20 mmol), ascorbic acid (36 mg, 0.20 mmol), KPi buffer (10 mL, pH 6, 0.3 M) and CH 3 CN (10 mL) was added methyl 4-oxobutanoate (32 µL, 0.31 mmol). The mixture was stirred at 60 for 18 h under argon. Then 1 M Na 2 CO 3 was added to adjust the pH to 7.5 and the reaction was stirred for another 3 h at 60 o C. The mixture was extracted with ethyl acetate (3 × 10 mL), the organic layer was dried (Na 2 SO 4 ) and evaporated. The residue was re-suspended in aq. HCl (10 mL, 1 M) and DMC (10 mL), and the aqueous layer was washed with DMC (2 × 5 mL). The DMC fractions were combined and washed with aq. HCl (2 × 5 mL, 1 M). The aqueous phase was evaporated to give 18 (25 mg, 57%), in a para:ortho ratio of 10:1, as a yellow solid. The spectroscopic characterization data was consistent with that given below for the NCS generated compound.
Synthesis of (S)-18. (i) Small-scale (1 mL) NCS reaction.
The procedure described on pS11 was used and reaction yield determined by HPLC. Compound (S)-18 was was formed in 57% yield (see Supplementary Figure 12C ) and no minor isomeric product was observed. The ee was determined to be 87% by chiral HPLC (see Supplementary Figure 6E and Table  S2 ).
(ii) Reaction for product isolation and characterisation. 2-(4-Fluoro-3-hydroxyphenyl)ethylamine 15 (12 mg, 0.053 mmol) and sodium ascorbate (9.0 mg, 0.045 mmol) were added to HEPES buffer (4.52 mL, pH 7.5, 100 mM). Methyl 4-oxobutanoate (9 µL, 0.075 mmol; 95% purity) in DMSO (10 µL) was added to the solution, followed by WT-△29TfNCS (final concentration 0.5 mg/mL) to a volume of 5 mL. The mixture was stirred at 37 o C under argon. After 15 h, the reaction was quenched with aq. HCl (0.5 mL) and adjusted to pH 7.5 by adding aq. 
Synthesis of (1S)-17. (i) Small-scale (1 mL) NCS reaction.
The procedure described on pS11 was used and reaction yield determined by HPLC. Compound (S)-17 was was formed in 76% yield (see Supplementary Figure 13D ). The ratio of (1S)-17, (1R)-17 and an ortho-product was confirmed to be 100:4:6 by 1 H NMR spectroscopy (SI Figure 14) and HPLC. (ii) Preparative scale reaction for product isolation and characterisation. Metaraminol (+)-bitartrate salt 14 (16.5 mg, 0.052 mmol) and sodium ascorbate (10.9 mg, 0.056 mmol) were dissolved in HEPES buffer (4 mL, pH 7.5, 100 mM). Methyl 4-oxobutanoate (8 µL, 0.075 mmol) in acetonitrile (0.5 mL) was added to the solution, followed by WT-△29TfNCS stock solution (final concentration 0.5 mg/mL) to make the total volume 5 mL. The mixture was stirred at 37 o C under argon.
After 18 h, the reaction was quenched with aq. HCl (1 mL, 1 M) and adjusted to pH 7.5 by adding aq. Na 2 CO 3 (1 M). The mixture was stirred for another 3 h at 60 o C under argon. The reaction mixture was then centrifuged, and the supernatant purified directly by C 18 preparative HPLC following the semipreparative HPLC method A to give a white solid (1S)-17 (6.0 mg, 49%). The ratio of isomers present was confirmed by 1 H NMR spectroscopy (SI Figure 14) 
